- 作者：A.C. Bay-Jensen&dagger ; ; acbj@nordicbioscience.com" class="auth_mail" title="E-mail the corresponding author ; D. Reker&dagger ; ; C.F. Kjelgaard-Petersen&dagger ; ; A. Mobasheri&Dagger ; ; § ; ; ‖ ; M.A. Karsdal&dagger ; ; C. Ladel¶ ; ; Y. Henrotin# ; C.S. Thudium&dagger ;
- 关键词：Biomarkers ; Osteoarthritis (OA) ; BIPED ; Year in a review
- 刊名：Osteoarthritis and Cartilage
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：24
- 期：1
- 页码：9-20
- 全文大小：369 K
c_2">Methods
PubMed was used as searching machine: Time period 2014/04/01–2015/05/01, MeSH term [Biomarker] AND [Osteoarthritis], Language; English, Full text available. Reviews were excluded. Only papers describing protein based biomarkers measured in human body fluids from OA patients were included.
c_3">Results
Biomarkers of joint tissue turnover, cytokines, chemokines and peptide arrays were measured in different cohorts and studies. Amongst those were previously tested biomarkers such as osteocalcin, Carboxy-terminal cross-linked fragment of type II collagen (CTX-II) and cartilage oligomeric matrix protein (COMP). A majority of the biomarker were classified as I, B or B biomarkers according to the BIPED criteria.
Work is continuing on testing biomarkers in OA. There is still a huge, unmet medical need to identify, test, validate and qualify novel and well-known biomarkers. A pre-requisite for this is better characterization and classification of biomarkers to their needs, which may not be reached before higher understanding of OA phenotypes has been gained. In addition, we provide some references to some recent guidelines from Food and Drug Administration (FDA) and European Medicines Agency (EMA) on qualification and usage of biomarkers for drug development and personalized medicine, which may provide value to the field.